Tobam Boosts Stock Holdings in Intuitive Surgical, Inc. $ISRG

Tobam grew its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 3,071.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,459 shares of the medical equipment provider’s stock after purchasing an additional 1,413 shares during the quarter. Tobam’s holdings in Intuitive Surgical were worth $826,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the business. Norges Bank purchased a new position in Intuitive Surgical during the fourth quarter valued at approximately $2,856,987,000. J. Stern & Co. LLP lifted its holdings in Intuitive Surgical by 18,504.6% during the fourth quarter. J. Stern & Co. LLP now owns 2,127,248 shares of the medical equipment provider’s stock worth $1,204,788,000 after buying an additional 2,115,814 shares during the period. Northwestern Mutual Wealth Management Co. lifted its holdings in Intuitive Surgical by 1,043.3% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,342,121 shares of the medical equipment provider’s stock worth $760,124,000 after buying an additional 1,224,734 shares during the period. Polen Capital Management LLC bought a new stake in Intuitive Surgical during the 4th quarter valued at $477,225,000. Finally, Assenagon Asset Management S.A. increased its holdings in shares of Intuitive Surgical by 106.6% in the 4th quarter. Assenagon Asset Management S.A. now owns 1,533,771 shares of the medical equipment provider’s stock valued at $868,667,000 after acquiring an additional 791,516 shares during the period. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Insiders Place Their Bets

In other news, SVP Iman Jeddi sold 5,625 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $420.55, for a total transaction of $2,365,593.75. Following the sale, the senior vice president owned 6,463 shares in the company, valued at approximately $2,718,014.65. The trade was a 46.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Amy L. Ladd sold 119 shares of the stock in a transaction that occurred on Wednesday, April 29th. The shares were sold at an average price of $463.50, for a total transaction of $55,156.50. Following the completion of the transaction, the director directly owned 120 shares of the company’s stock, valued at $55,620. The trade was a 49.79% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 7,169 shares of company stock valued at $3,059,135. 0.60% of the stock is currently owned by corporate insiders.

Intuitive Surgical Stock Performance

Shares of ISRG opened at $406.78 on Friday. The firm has a market cap of $144.07 billion, a PE ratio of 49.31, a P/E/G ratio of 3.31 and a beta of 1.46. Intuitive Surgical, Inc. has a 12 month low of $396.68 and a 12 month high of $603.88. The stock has a fifty day moving average price of $438.43 and a 200-day moving average price of $490.46.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Tuesday, April 21st. The medical equipment provider reported $2.50 earnings per share for the quarter, topping the consensus estimate of $2.08 by $0.42. Intuitive Surgical had a return on equity of 15.98% and a net margin of 28.15%.The firm had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.62 billion. During the same period in the previous year, the business earned $1.81 EPS. The firm’s revenue for the quarter was up 23.0% on a year-over-year basis. As a group, research analysts forecast that Intuitive Surgical, Inc. will post 8.57 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently commented on ISRG. Zacks Research lowered Intuitive Surgical from a “strong-buy” rating to a “hold” rating in a research report on Monday, March 30th. Robert W. Baird raised their price objective on Intuitive Surgical from $575.00 to $610.00 and gave the company an “outperform” rating in a research report on Wednesday, April 22nd. HSBC reduced their target price on shares of Intuitive Surgical from $653.00 to $604.00 and set a “buy” rating for the company in a report on Wednesday, April 22nd. Weiss Ratings reissued a “hold (c)” rating on shares of Intuitive Surgical in a research report on Tuesday, May 19th. Finally, TD Cowen lowered their price target on shares of Intuitive Surgical from $660.00 to $585.00 and set a “buy” rating on the stock in a report on Wednesday, April 22nd. Nineteen analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $573.42.

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.